Brought to you by 
Vernalis, Lilly develop VML 670 to treat sexual dysfunction
27 Apr 2021
Executive Summary
Vernalis Group (neuroscience and CNS drugs) will collaborate with Eli Lilly to develop VML 670--discovered by Lilly and licensed to Vernalis--as a treatment for sexual dysfunction.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vernalis, Lilly develop VML 670 to treat sexual dysfunction
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice